

Krsnaa Diagnostics Ltd

Call: BUY at CMP 691

Target Price: 865 (upside 25%)

The company's outstanding service offerings, distinguished by their competitive pricing, have been instrumental in stimulating patient visits and increasing test volumes.

- ✓ The revenue for Q3FY24 amounted to INR 1,583 million, representing a substantial 34% increase compared to the same period last year, and a modest 2% increase compared to the previous quarter. EBITDA stood at 374 million, showing a notable 18% increase from the previous quarter and a significant 27% increase from the same quarter last year. The EBITDA margin was recorded at 24%, reflecting a noteworthy improvement of 217 basis points from the previous quarter and 128 basis points from the same quarter last year. However, the PAT stood at INR 130 million, indicating a commendable 24% increase from the previous quarter but a slight decline of 5% from the same quarter last year.
- Krsnaa has secured notable opportunities in the healthcare sector, with its selection to offer 17 MRI and 17 CT scan services in Maharashtra, alongside being chosen to provide MRI services across five districts in Madhya Pradesh. Additionally, the company has successfully obtained a contract to conduct HPLC tests in 21 districts within Maharashtra. Moreover, Krsnaa has made significant strides by launching its pathology project in Assam, marking a new operational venture. Furthermore, the company has enhanced its nationwide presence by establishing 195 new centers, thereby solidifying its footprint in the healthcare industry.
- The company is pleased to announce the successful completion of an agreement pertaining to the Assam Pathology tender, marking a significant milestone. This endeavor encompasses the establishment of 10 labs and 1,256 collection centers, presenting a substantial opportunity for expansion. With this development, their presence in Assam is significantly bolstered, now extending across all districts of the region. Furthermore, Krsnaa Diagnostics is strategically positioned to deploy 54 CT Scan machines, 24 MRI machines, establish 156 labs, and set up 2,768 collection centers, all governed by various contractual agreements.
- ✓ Despite investing INR 1,500 million in capital expenditures, Krsnaa consistently maintains positive cash flow, largely attributable to their strategic approach to machine acquisition, which facilitates a robust cash flow conversion cycle and efficient management of working capital.

Valuation:

Due to the steadfast dedication of the company to its expansion strategy, which involves gradually extending its reach throughout India by securing bids and venturing into new states, we foresee a promising path for the stock. Our assessment of its worth indicates a target price of INR 865, taking into account a target PE ratio of 25x and an anticipated EPS of INR 34.60 for FY26E.

Forefront Innovators Spearheading the Transformation of the **Diagnostic Industry**

Key Stock Data	
Bloomberg	KRSNAA:IN
Sector	Healthcare
Mkt Cap. (INR. bn)	22.16
CMP	696
NIFTY	865
O/s Shares (mn)	32.29
52 Week High / Low (INR.)	789/354
Face Value (INR.)	5.0
Shareholding (%)	Q3FY24
Promoters	27.1%
DIIs	16.6%
FIIs	03.4%
Others	52.9%

Financial Ratios						
	FY24E	FY25E	FY26E			
ROE %	8%	11%	11%			
ROCE%	8%	11%	12%			
P/E (x)	36X	24X	20X			

1 Year Relative Price Chart



KRSNAA

Contact us on:

(91-22) 6651-0111


uljkresearch@uljk.in

Financial Snapshot

Figures (in mn)	Q3FY24	Q3FY23	Y-o-Y(%)	Q2FY24	Q-o-Q(%)	FY23A	FY24E	FY25E	FY26E
Revenues	1,583	1,181	34%	1,554	2%	4,871	6,108	8,530	9,834
EBITDA	374	294	27%	318	18%	1,223	1,374	1,962	2,311
EBITDA Margins %	24%	25%	-128bps	20%	317bps	25%	23%	23%	24%
PAT	130	136	-5%	105	24%	621	604	915	1,087
PAT Margins %	8%	12%	-336bps	7%	144bps	13%	10%	11%	11%
EPS	4.09	4.35	-6%	3.35	22%	19.78	19.25	29.15	34.60

Source: Company, ULJK Research ULJK research reports are available on Bloomberg (ULJK <Go>)









Exhibit 3: As EBITDA shows signs of improvement, we can also anticipate a corresponding enhancement in the company's PAT. (INR mn)



Source: Company, ULJK Research


Source: Company, ULJK Research

Source: Company, ULJK Research

Exhibit 5 : The fluctuation in margins primarily stems from the expansion plans, resulting in increased operating expenses.




by the increasing number of patient visits. (INR mn)




Source: Company, ULJK Research

Exhibit 4: Company's revenue split



Source: Company, ULJK Research

Exhibit 6: Over the past few quarters, there has been a representation of revenue, EBITDA, and PAT figures. 1,583 1.554



Source: Company, ULJK Research



Company Overview

Krsnaa Diagnostics Ltd. emerges as a rapidly expanding diagnostic services provider in India, excelling in both Radiology and Pathology. Since its inception in 2011, starting with just two radiology centers, the company has achieved remarkable growth. Currently, it spans across 15 states and 2 Union Territories, boasting a network of over 3,000 centers nationwide. The core mission of Krsnaa Diagnostics revolves around ensuring easy accessibility and affordability of top-tier diagnostic services for all individuals. This commitment defines their identity and sets them apart in the industry.Leveraging collaborative teleradiology services, Krsnaa Diagnostics strives to deliver clinical excellence, facilitating evidence-based treatment for patients across the country, regardless of their location. Their infrastructure is supported by cutting-edge technology, including an advanced cloud-based PACS workflow, enabling swift deployment and seamless integration to meet diverse operational requirements. Backed by a team of highly qualified Radiologists and Pathologists worldwide, Krsnaa Diagnostics ensures the delivery of accurate reports. Their services are characterized by prompt turnaround times for diagnostic reports, convenient access to consultations with their specialized team, and efficient handling of diagnostic needs.

Sector Overview

In the medium term, the healthcare delivery market in India is poised for substantial growth. As per CRISIL Research, the industry is anticipated to surpass pre-Covid levels in FY22 and maintain a compound annual growth rate (CAGR) of 10-12% from FY22 to FY27. This growth trajectory is underpinned by enduring structural factors, strong fundamentals, and improving affordability within the sector. The expansion of the Ayushman Bharat scheme is further expected to bolster growth prospects. Moreover, the revival of lucrative medical tourism, facilitated by the easing of international travel restrictions, presents additional avenues for positive development.

In comparison to other sectors, the healthcare industry in India has notably trailed, primarily attributed to a deficiency in innovation. The pandemic underscored the importance of remote medical services, facilitated by digitization and automation. Given India's dense population, there's a pressing need for technologically advanced, high-quality medical services accessible at affordable rates nationwide. Key drivers propelling growth in India's healthcare market include rapid urbanization, an aging populace, and a surge in chronic diseases. This sector, encompassing hospitals, diagnostic centers, pharmaceutical firms, and health insurance providers, is experiencing rapid expansion due to the rising prevalence of health issues affecting individuals across all age demographics.

Key Concall Highlights Q3FY24

- ✓ In FY '25, the company intends to allocate INR 1,500-1,800 million towards new projects, encompassing initiatives such as the Maharashtra MRI tender, M.P MRI tender and BMC Project.
- ✓ Krsnaa is continuously investigating new testing capacities to meet the changing demands of both its patients. and customers.
- ✓ The company aims to broaden its geographical footprint through inorganic expansion, particularly by acquiring regional local players.
- ✓ The anticipated CapEx for the Rajasthan project ranges from INR 2000 to 2500 mn, to be spent over a one-year period.
- √ The company is actively seeking alternatives to reduce capital expenditure and transition towards an assetlight model.

Key things to look out for:

- √ The company is bound by government regulations imposing price ceilings on its services, potentially posing a negative impact on its revenue and profitability.
- ✓ The presence of numerous government regulations and a significant concentration of local diagnostic centers in various regions pose challenges in expanding into new geographies.



Income Statement (INR mn)	2023A	2024E	2025E	2026E
Revenue from operation	4,871	6,108	8,530	10,113
Op. Expenses	3,648	4,734	6,397	7,584
EBITDA	1,223	1,374	2,132	2,528
Depreciation & Amortisation	538	705	979	1,129
EBIT	685	670	1,153	1,399
Finance cost & other Income	77	105	122	130
Other Income	194	201	223	240
PBT	802	765	1,255	1,509
Total tax expense	181	161	301	362
PAT	621	605	954	1,147
Cash Flow Statement (INR mn)	2023A	2024E	2025E	2026E
PBT	802	765	1,255	1,509
Add: Dep & Amort	538	705	979	1,129
Other	-90	-96	-101	-110
Changes in working capital	-356	28	-113	-68
Less: Taxes paid	-131	-161	-301	-362
Cash flow from Operating	763	1,242	1,719	2,098
Cash flow from Investing	-1,089	-1,799	-1,277	-1,260
Cash flow from Financing	-331	-158	-178	-171
Net Cash flow	-657	-715	264	667
Opening balance	884	227	-489	-225
Short term deposits	861	861	861	861
Closing balance	1,088	372	636	1,303
Margins (%)	2023A	2024E	2025E	2026E
EBITDA Margin	25.1%	22.5%	25.0%	25.0%
EBIT Margin	14.1%	11.0%	13.5%	13.8%
PAT Margin	12.8%	9.9%	11.2%	11.3%
Financial Ratios				
Particulars	2023A	2024E	2025E	2026E
Return on Capital employed (%)	8.9%	8.2%	11.5%	12.4%
	8.7%	7.9%	11.3%	12.0%
Return on Equity (%)				
EPS	19.78	19.25	30.37	36.52
' ' '		19.25 36.0	30.37 24.0	36.52 20.0

Other Financial assets Cash and cash equivalents Other Current asset Current Assets Inventories Trade receivable Other Financial assets Cash and cash equivalents Other Current asset	9,099 4,933 3 28 1877 251 731 118 1,088 70	9,866 6,229 3 28 1877 314 837 118 372 88	6,749 3 28 1877 439 1,168 118 636 123	7,120 3 28 1877 521 1,385 118 1,303 146
Intangible Asset Other non current asset Current Assets Inventories Trade receivable Other Financial assets	4,933 3 28 1877 251 731 118	6,229 3 28 1877 314 837 118	6,749 3 28 1877 439 1,168 118	7,120 3 28 1877 521 1,385 118
Intangible Asset Other non current asset Current Assets Inventories Trade receivable	4,933 3 28 1877 251 731	6,229 3 28 1877 314 837	6,749 3 28 1877 439 1,168	7,120 3 28 1877 521 1,385
Intangible Asset Other non current asset Current Assets Inventories	4,933 3 28 1877 251	6,229 3 28 1877 314	6,749 3 28 1877 439	7,120 3 28 1877 521
Intangible Asset Other non current asset Current Assets	4,933 3 28 1877	6,229 3 28 1877	6,749 3 28 1877	7,120 3 28 1877
Intangible Asset Other non current asset	4,933 3 28	6,229 3 28	6,749 3 28	7,120 3 28
Intangible Asset	4,933 3 28	6,229 3 28	6,749 3 28	7,120 3 28
	4,933	6,229	6,749	7,120
	4,933	6,229	6,749	7,120
Financial Assets		<u> </u>	· ·	
Fixed Assets	9,099	9,866	11,142	12,301
Non-current assets	9,099	9,866	,	12,301
Total Equity & Liabilities			11,142	12,501
Total Liabilities	1,712	1,874	2,196	2,409
Other current liabilities	23	23	23	23
Other financial liabilities	244	244	244	244
Trade payables	621	837	1,215	1,468
Lease liabilities	22	22	22	22
Borrowings	82	82	82	82
Current Liabilities	349	349	349	349
Other non-current liabilities	349	349	349	349
Deferred Tax Liabilities	128	128	128	128
Lease Liabilities	0	0	0	0
Borrowings	243	190	134	93
Non-current liabilities				
Liabilities	7,307	1,332	0,540	10,032
Total Equity	7,387	7,992	8.946	10,092
Non-controlling interest	7,230	7,833	0,769	9,933
Equity share capital Reserves & Surplus	7,230	7,835	8,789	157 9,935
Equity and liabilities	157	157	157	157
Balance Sheet (INR mn)	2023A	2024E	2025E	2026E
	20224	20245	20255	20265

Source: Company, ULJK Research

Source: Company, ULJK Research



Source: Bloomberg


ULJK returns compared to peers

Period (months)	ULJK Average Return %	Peers Average Return %	Outperformance/Underperformed compared to peers
1	6.32%	3.65%	73.2%
3	16.52%	9.99%	65.4%
6	33.72%	20.23%	66.7%
12	51.55%	35.06%	47.0%
24	51.90%	34.89%	48.8%
36	96.50%	75.69%	27.5%


ULJK's 229 Companies Under Coverage							
Aavas Financiers Ltd	CESC Ltd	Hindustan Petroleum Corporation Ltd	Mangalore Chemicals & Fertilizers Ltd	Spandana Spoorthy Financial Ltd			
ABB India Ltd	Cipla Ltd	Home First Finance Company	Marksans Pharma Ltd	SRF Ltd			
ABB Power Products and Systems Ltd	City Union Bank Ltd	HT Media Ltd	Maruti Suzuki India Ltd	State Bank Of India			
ACC Ltd	Coal India Ltd	ICICI Bank Ltd	Mazagon Dock Shipbuilders Ltd	Steel Authority Of India Ltd			
Adani Ports and Special Economic Zone	Coforge Ltd	ICICI Lombard GIC Ltd	Minda Corporation Ltd	Stove Kraft Ltd			
Adani Power Ltd	Container Corporation Of India Ltd	IDBI Bank Ltd	Mindtree Ltd	Sun Pharmaceuticals Ltd			
Adani Wilmar Ltd	Cummins India Ltd	IDFC First Bank Ltd	Monte Carlo Fashion Ltd	Sun TV Network Ltd			
Aether Industries ltd.	Data Patterns Ltd	India Pesticides Ltd	Motherson Sumi Systems Ltd	Sunteck Realty Ltd			
Affle (India) Ltd	Devyani International Ltd	Indiabulls Housing Finance	Nath Industries Ltd	Syngene International Ltd			
Amber Enterprises India Ltd	Dhampur Sugar Mills Ltd	Indiabulls realestate Ltd	Nelco Ltd	Tata Chemicals ltd.			
Ambuja Cements Ltd	DLF Ltd	Indian Bank Ltd	New India Assurance	Tata Communications Ltd			
AMI organics	Dr Reddy's Laboratories Ltd	Indian Hotels Company Ltd	Newgen Software Solutions Ltd.	Tata consultancy services Ltd			
Anupam Rasayan India Limited	Dreamfolks Services Ltd	Indian Oil Corporation Ltd	NMDC Ltd	Tata Motors Dvr Ltd			
APL Apollo Tubes Ltd	Dynamatic Technologies Ltd	Indian Railway Catering and Tourism Corporation Ltd	NTPC Ltd	Tata Motors Ltd			
Apollo Tyres Ltd	Eclerx Services Ltd	Indo Count Industries Ltd	Oil and Natural Gas Corporation Ltd	Tata Power Co. Ltd			
Arvind Ltd	Eris Lifesciences Ltd	Indoco Remedies Ltd	Oriental Carbon & Chemicals Ltd	Tata Steel Ltd			
Asahi India Glass Ltd	Eveready Industries India Ltd	Indus Tower Ltd	Parag Milk Foods Ltd	Tech Mahindra Ltd			
Ashok Leyland Ltd	Everest Kanto Cylinder Ltd	Infibeam Avenues Ltd	Parsynath Developers	Technocraft Industries (India) Ltd			
Atul Ltd	Exide Industries Ltd	IRCON International Ltd	Parsvnath Developers Ltd	Tejas Network Ltd			
Au Small Finance Bank Ltd	Expleo Solutions Ltd	ITC ltd	Pennar Industries Ltd	Titagarh Rail Systems Ltd			
Aurobindo Pharma Ltd	Federal Bank Ltd	ITD Cementation Ltd	Pfizer Ltd	Torrent Power Ltd			
Axis Bank Ltd	Filatex India Ltd	Jaiprakash Power Venture Ltd	Piramal Enterprises Ltd	Triveni Engineering & Industries Lt			
Bajaj Healthcare Ltd	Firstsource Solution Ltd	Jindal SAW Ltd	Poonawalla Fincorp Ltd	TVS Motor Company Ltd			
		Jindal Steel & Power Ltd	Power Finance Corporation Ltd	UGRO Capital			
Balrampur Chini Bandhan Bank Ltd	Fortis Healthcare Ltd Gail (India) Ltd	Jindai Steel & Power Ltd JSW Steel Ltd					
	Gail (India) Ltd		Power Grid Corporation Of India	Ujjivan Financial Services Ltd			
Bank of Baroda		Jubilant Ingrevia Ltd	Praj Industries Ltd	United Drilling Ltd			
Bank of India	GET&D India Ltd	Jubilant Pharmova Ltd	Prestige estates Projects Ltd	United Spirits Ltd			
BASF India Ltd	GHCLLTD	Just Dial Ltd	Punjab National Bank	UPL ltd			
Bata India Ltd	Gland Pharma Ltd	Jyothy Labs Ltd	PVR Ltd	Valiant Organics Ltd.			
BF Utilities Ltd	Glenmark Pharmaceuticals Ltd	Kajaria Ceramics	Quess corp Ltd	Verroc Engineering Ltd.			
Bharat Bijlee Ltd	Godfrey Phillips India Ltd	KEC INTERNATIONAL LTD	Quick Heal Technologies Ltd	Vedanta Ltd			
Bharat Electronics Ltd	Graphite India Ltd	Kernex Microsystem India Ltd	Railtel Corportaion Of India	V-guard industries Ltd			
Bharat Forge Ltd	Greaves Cotton Ltd	Kotak Bank Ltd	RBL Bank Ltd	Varun Beverages Ltd			
Bharat Heavy Electricals Ltd	Gujarat Fluorochemicals Ltd	Krishna Institute of Medical Sciences Ltd.	Reliance Industries Ltd	Voltas Ltd			
Bharat Petroleum Corp Ltd	General Insurance Corporation of India	L&T finance holdings Ltd	RVNL LTD	Vinati Organics Ltd			
Bharti Airtel Ltd	Happiest Minds Technologies Ltd	L&T Financial Holdings Ltd	Sadbhav Infrastructure Project Ltd	Welspun Corp Ltd			
Birla Corporation Ltd	HBL POWER SYSTEMS LTD	larsen & Toubro ltd	SAKSOFT Ltd	Welspun Enterprises Ltd			
Blue Star Ltd	HCL Technologies Ltd	Larsen & Tourbo Infotech Ltd	Sanghi Industries	Welspun India Ltd			
BSE Ltd	HDFC bank ltd	Laurus Labs Ltd	Schneider Electric	Yes Bank Ltd			
Cadila Healthcare Ltd	HDFC Ltd	LIC Housing Finance Ltd	Shalby Ltd	Zee Entertainment Enterprises Ltd			
Can Fin Homes Ltd	HEG Ltd	Lupin Ltd	Shilpa Medicare Ltd	Zensar Technologies Ltd			
Canara Bank	Heranba Industries Ltd	Life Insurance Corporation of India	Shree Cement Ltd	ZF Steering Gear India Ltd			
Care Ratings Ltd	Himadri Speciality Chemical Ltd	Mahanagar Gas Ltd	Shree Renuka Sugars Ltd	Zomato Ltd			
CDSLLtd	Himatsingka Seida Ltd	Mahindra & Mahindra Ltd	Siemens Ltd	Zydus Lifesciences Ltd			
Century Textiles and Industries Ltd	Hindalco Industries Ltd	Mahindra Holidays and Resorts India Ltd	Solar Industries Pvt Ltd	Zydus Wellness Ltd			
Chemplast Sanmar Ltd	Hindustan Oil Exploration Co. Ltd	Man Infraconstruction Ltd	SP Apparel Ltd				




ULJK's Performance Tracker




ULJK's Open Calls – Sector wise



Average Returns of Top Performing Stocks



Time wise (Days) to % Average Returns





		Total Ca	lls review: Closed Calls:	201				
Stocks	Sector	Туре	Call Date	Call Price	Target	Exit Date	No of Days	Total Return %
Adani Power Ltd	Energy, Oil & Petroleum	BUY	11/19/2020	40	200	4/1/2022	498	400%
JSW energy Ltd	Energy, Oil & Petroleum	BUY	4/9/2021	88	388	9/30/2021	174	34. %
TATA Motors Ltd	Automotive & Ancillary	BUY	7/7/2020	103	448	10/1 /2 21	463	J35 /
SAIL Ltd	Metals & Mining	BUY	7/9/2020			4/30/2021	295	300%
Dynamatic Technologies Ltd	Capital Goods	BUY	2/15/24	869	3175	9/13/2021	209	266%
Filatex India Ltd	Te ti s	M	12/9/2020	138	13,0	1/14/2022	401	255%
GHCI 17d	Chemicals	BVD	-U17/2025	164	557	3/22/2022	561	240%
upor C Ltd	erage	BUY	11/19/2020	1,37	4470	11/6/2021	352	225%
Ashok Leyland Ltd	Automotive & Ancillary	BIA	D3/1/22 ·	52	165	9/3/2022	798	217%
Nelco Ltd	Avera	BUY	1/18/2021	208	643	9/28/2021	253	209%
Monte Carlo Fashions Ltd	Apparels & Accessories	BUY	12/21/2020	256	752	7/4/2022	560	194%
First source solutions Ltd	IT	BUY	8/10/2020	54	150	6/3/2021	297	177%
Eclerx Services Ltd	IT	BUY	12/28/2020	894	2455	9/16/2021	262	175%
Tata Chemicals Ltd	Chemicals	BUY	11/19/2020	352	949	D 6 5/2 A	320	170%
Mangalore Chemicals Ltd	Chemicals	BUY	1 7 9/12 €	J7.P	112	4/8/2022	485	167%
Indian Bank Ltd	BFSI	VY	8/20/2020	64	170	019/18/2021	424	166%
State Bank of Inc a 1 to	BECI	BUY	7/7/2020	ns:	D ⁴	9/17/2021	437	154%
NMDC Ltd	Metals & Mining	øe	<u>C/2020</u>	81	203	5/12/2021	315	151%
HEG Ltd	eanit Goods	BUY	12/23/2020	865	200	4/2/2021	100	132%
Greaves Cotton Ltd	Capital Goods	ra	6 (8/27) 2020	86	197	1/10/2022	501	129%
Larsen & Toubro Ltd	Congloruerate	BUY	7/3/2020	941	2092	11/25/2022	875	122%
Graphite India Ltd	Capital Goods	BUY	12/23/2020	285	630	4/3/2021	101	121%
Tata steel Ltd	Metals & Mining	BUY	12/28/2020	634	1391	7/29/2021	213	119%
Stove Kraft Ltd	Consumer Goods & Utilities	BUY	5/14/2021	490	1052	9/28/2021	137	115%
ONGC Ltd	Energy, Oil & Petroleum	BUY	10/19/2020	72	154	11/5/2021	382	114%
Minda Corp Ltd Ltd	Automotive & Ancillary	BUY	8/21/2020	80	170	11/1/2021	437	113%
Wockhardt Ltd Ltd	Pharmaceuticals	BUY	11/19/2020	332	685	5/19/2021	181	106%
NALCO Ltd Ltd	Metals & Mining	BUY	7/9/2020	36	74	5/7/2021	302	106%
Eveready Industries India Ltd Ltd	Consumer Goods & Utilities	BUY	1/11/2021	199	401	8/3/2021	204	102%
Mindtree Ltd	п	BUY	3/15/2021	1935	3800	11/15/2022	610	96%







General Disclaimer

This report has been prepared by the research department of ULIK Research, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. For full disclaimer please log on to https://www.uljk.in/disclaimer.html

Contact Info Tel: 022 - 6651 0111/66510110

Research Analyst Registration No

INH000006518

Disclosure Appendix

Analyst Certification

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and no part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

General Disclaimer

This report has been prepared by the research department of ULIK Research, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal.

We have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

ULJK Research or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ULJK Research or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. The above Research Report is meant for internal circulation for ULJK Research.

ULJK Research and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to ULJK Research or any of its affiliates to any registration or licensing requirement within such jurisdiction.